Today: 29 April 2026
Browse Category

NASDAQ:INFA 30 June 2025 - 27 November 2025

Salesforce (CRM) Stock Before the Bell: AI Bets, Informatica Deal and Cybersecurity Risks – What to Watch on November 28, 2025

Salesforce (CRM) Stock Before the Bell: AI Bets, Informatica Deal and Cybersecurity Risks – What to Watch on November 28, 2025

Salesforce shares closed at $228.27 on November 26, down 2.5% for the day and about 30% year-to-date. The company faces ongoing fallout from a Gainsight-related cybersecurity breach and just completed its Informatica acquisition. Q3 fiscal 2026 earnings are due December 3, with Wall Street expecting revenue near $10.27 billion and EPS of $2.85.
27 November 2025
······
Salesforce Stock Soars After Dreamforce AI Bombshell – What Investors Need to Know (Oct. 21, 2025)

Salesforce Stock Soars After Dreamforce AI Bombshell – What Investors Need to Know (Oct. 21, 2025)

Salesforce shares rose about 4–7% in mid-October after CEO Marc Benioff set a new FY2030 revenue target above $60 billion and detailed new AI integrations at Dreamforce. CRM opened at $254 on Oct. 21 and traded into the $260s, rebounding from multi-month lows. Q2 FY2026 results beat forecasts, but Q3 guidance was soft. Analysts remain cautiously optimistic, with an average 12-month target near $330.
21 October 2025
··········
AI-Powered Report Generators Are Revolutionizing Data Analysis Across Industries

AI-Powered Report Generators Are Revolutionizing Data Analysis Across Industries

Gartner forecasts that by 2025, about 75% of analytics stories will be auto-generated through data storytelling. Power BI Copilot and Tableau’s AI features now produce reports and narratives from user prompts, pulling data from sources like Azure and Excel. Tableau acquired Narrative Science in 2022, integrating its natural-language data-story capabilities. Experts caution that data quality remains essential for reliable AI-generated reports.
5 July 2025
·····
Cloud Computing and XaaS Developments (May–June 2025)

Cloud Computing and XaaS Developments (May–June 2025)

Salesforce agreed to acquire Informatica for $8 billion in May 2025. Microsoft partnered with xAI to host Grok 3 models on Azure. Red Hat and AMD expanded AI collaboration, while IBM and Oracle launched a cloud partnership. Q1 2025 global enterprise cloud infrastructure spending reached $94 billion, up 23% year over year.
30 June 2025
··········

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop